Betta Pharmaceuticals Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Public, Subsidiary
- Established
- 2003-01-07
- Employees
- 1.9K
- Market Cap
- -
- Website
- https://www.bettapharma.com
Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH
- Conditions
- Interventions
- First Posted Date
- 2013-05-17
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT01855854
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients
- First Posted Date
- 2013-04-30
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT01843647
- Locations
- 🇨🇳
Zhejiang cancer hospital, Hangzhou, Zhejiang, China
Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy
- First Posted Date
- 2012-11-02
- Last Posted Date
- 2015-05-22
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT01720901
- Locations
- 🇨🇳
Xiangya Hospital, Central-South Univercity, Changsha, Hunan, China
Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients
- First Posted Date
- 2012-11-01
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 296
- Registration Number
- NCT01719536
- Locations
- 🇨🇳
The First Affiliated Hospital of Anhui Medical Univercity, Hefei, Anhui, China
🇨🇳Chinese People's Liberation Army (PLA) General Hospital, Beijing, Beijing, China
🇨🇳Beijing Hospital for Chest Tumors & Tuberculosis Diseases, Beijing, Beijing, China
Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment
- Conditions
- Interventions
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT01707329
- Locations
- 🇨🇳
Hunan Province Tumor Hospital, Changsha, Hunan, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
🇨🇳The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT01690390
- Locations
- 🇨🇳
The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang, China
🇨🇳Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang, China
🇨🇳Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China
Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2012-08-15
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT01665417
- Locations
- 🇨🇳
Chinese People's Liberation Army (PLA) General Hospital, Beijing, Beijing, China
First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT01646450
- Locations
- 🇨🇳
Shanghai Chest Hospital Affliated to Shanghai Jiaotong Univercity, Shanghai, Shanghai, China
Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation
- Conditions
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT01516983
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose
- First Posted Date
- 2011-11-04
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT01465243
- Locations
- 🇨🇳
307 Hospital of People's Liberation Army（PLA）, Beijing, Beijing, China